All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Portage Biotech Inc., of Toronto, said its Biohaven unit started dosing subjects in the first study testing the pharmacokinetics and safety of BHV-4157.
